NZ-1 is an anti-PDPN antibody and, in the research established by Kato et al., the authors used the antibodies derived from NZ-1 and demonstrated an anti-tumor effect using the xenograft models of glioma, mesothelioma, lung cancer, and others [76,77]. Here, PDPN is linked to neoplasm.